Background: Vitamin D is a hormone regulating not only calcium and phosphate homeostasis but also, at the same time, exerting many other extraskeletal functions via genomic effects (gene transcription) and probably by non-genomic effects as well. Availability is ensured by dietary intake of its precursors and by de novo production via sunlight. Yet, vitamin D deficiency and insufficiency are very common across the globe and are connected to many pathophysiological states, for example, diabetes mellitus, allergies, autoimmune diseases, pregnancy complications, and recently have also been associated with worse COVID-19 clinical outcomes. Summary: In this review, we summarize current knowledge about vitamin D metabolism in general, its role in diabetes mellitus (mainly type 2) and diabetic complications (mainly diabetic kidney disease), and potential therapeutic perspectives including vitamin D signalling as a druggable target. Key Messages: Vitamin D is not only a vitamin but also a hormone involved in many physiological processes. Its insufficiency or deficiency can lead to many pathological states.

Despite the significant effort in the last century to eradicate or minimize vitamin D deficiency among the population, especially children, there is still a high prevalence for vitamin D insufficiency/deficiency worldwide [1, 2]. Vitamin D deficiency and insufficiency are also more common across type 2 diabetes mellitus (T2DM) patients. Furthermore, some authors suggest that vitamin D deficiency may be a prominent element of CKD. Vitamin D has to be metabolically activated in the kidney, and patients with CKD including diabetic kidney disease (DKD) are not able to produce enough of the active form of vitamin D (1,25(OH)2D). Vice versa, the kidneys are assumed to be a classical 1,25(OH)2D target. Hence, the vitamin D receptor (VDR) is highly expressed in kidney tissue [3-5]. Impairment of the capability of the kidney to produce and reuptake enough calcitriol and therefore maintain vitamin D, phosphate, and calcium homeostasis is one of the principal pathophysiological components of metabolic bone disease in CKD. Also, urinary loss of both vitamin D and vitamin D binding protein (VDBP) has been reported in these individuals. With vitamin D concentration decreasing over time, clinical outcomes are worsening. DKD, one of the most common forms of CKD, accounts for almost 50% of end-stage kidney disease in developed countries requiring renal replacement therapy. DKD – by itself and mostly during haemodialysis – also highly increases the risk of cardiovascular diseases such as heart attack, stroke, and others [1, 6].

Vitamin D is a lipid-soluble hormone and micronutrient whose primary function is to regulate calcium and phosphorus homeostasis. Vitamin D deficiency has been linked to rickets over 100 years ago. However, it has much broader effects mediated by genomic (vitamin D directly or indirectly influences expression of up to 2,000 genes) as well as non-genomic mechanisms [1]. Vitamin D deficiency also contributes to many extraskeletal outcomes, including higher risk of type 1 or type 2 diabetes mellitus, allergy, autoimmunity, pregnancy complications, and many other pathologies. A meta-analysis from 2017 connected low levels of vitamin D with a higher risk of respiratory tract infections [7]. A recent retrospective multicentre study statistically significantly associated lower levels of 25(OH)D with mild rather than severe CO-VID-19 outcomes [8]. The aims of this review are (i) to summarize recent advances in the understanding of vitamin D metabolism, (ii) to highlight its importance for human health, and (iii) to describe its role in the development of T2DM and DKD.

General term vitamin D refers to the group of lipid-soluble secosterols, also known as calciferols. Most vitamin D is produced in the skin (approximately 80%) and remaining 20% is from the dietary precursors. In the upper layers of the skin, the vitamin D precursor 7-dehydrocholesterol is converted to previtamin D3 by UVB irradiation. Previtamin D3 then undergoes a thermal-induced rearrangement to form cholecalciferol (vitamin D3) in lower layers of the skin. This thermal process seems to be a rate-limiting step in vitamin D3 synthesis [9]. Vitamin D is also acquired from the diet in the form of cholecalciferol and ergocalciferol (vitamin D2). Vitamin D3, with half-life approximately 12 h [10], binds to VDBP which enables its transport in the blood. In the liver, carbon 25 is hydroxylated to form 25-hydroxyvitamin D3 (25(OH)D3). Several enzymes have 25-hydroxylase activity; however, most important are CYP2R1 and CYP27A1 [11, 12]. CYP2R1 can hydroxylate both vitamin D2 and D3 equally, while CYP27A1 hydroxylates vitamin D3 preferably [13]. 25-Hydroxylation is a highly efficient process; about 75% of vitamin D is hydroxylated during the first pass through the liver [14]. The rate of 25-hydroxylation seems to be less regulated compared to C-1α hydroxylation and instead depends predominantly on D2 or D3 availability [15]. Increasing evidence suggests that CYP2R1 is a major C25 hydroxylation enzyme [15, 16]. Mutation L99P in the CYP2R1 gene eliminates its C25 hydroxylation activity, and individuals carrying this mutation suffer from vitamin D deficiency. Table 1 summarizes all mentioned CYPs in this review with the respective cell localization, substrate, and final products.

Table 1.

Summary of CYP enzymes involved in the metabolism of vitamin D

Summary of CYP enzymes involved in the metabolism of vitamin D
Summary of CYP enzymes involved in the metabolism of vitamin D

25(OH)D is the main form of vitamin D circulating in the blood with half-life approximately 20 days [10] commonly used as an indicator of vitamin D status. However, it should be noted that 1,25(OH)2D has approximately 1,000× lower plasma concentration than 25(OH)D, and its concentration may be sufficient or elevated even if 25(OH)D is decreased. Nonetheless, an active form of vitamin D is 1,25(OH)2D, also known as calcitriol, principally formed by CYP27B1 in mitochondria of proximal tubule cells (PTC) in the kidney [17]. Furthermore, 1α hydroxylation occurs also in other cell types, including parathyroid gland, cells of the immune system, or various epithelial cells [11, 12]. This metabolic activation will be discussed further.

25-Hydroxyvitamin D-24-hydroxylase (CYP24A1) is an enzyme responsible for 25(OH)D and 1,25(OH)2D catabolism. Both forms can be degraded in two pathways. Mainly via C24 hydroxylation to form 24,25(OH)2D and 1,24,25(OH)3D which is then degraded to calcitroic acid. Another possibility is C23 hydroxylation which produces (1,)23,25(OH)3D and 1,25(OH)2D-26S,23-lactone as a final product [18]. Both metabolites are preferably excreted through bile into faeces, and only a small portion appears in the urine as 1,25(OH)2D-26S,23-lactone forms a complex with VDBP [19] which is taken up by the PTC via the megalin/cubilin transporting system [20]. Human CYP24A1 is capable of hydroxylating both C23 and C24 with predominance to the C24 hydroxylation pathway [18]. Prosser et al. [21] showed that A326G mutation in the CYP24A1 gene causes shift of this ratio to the favour of the C23 hydroxylation pathway. Calcitroic acid is rapidly excreted into bile with no known biological activity [22]. The exact reason why two degradation pathways exist is not known. Some authors suggest that the C23 pathway exists as a backup [9] or safety mechanism to rapidly degrade abundant calcitriol [21]. The importance of precise maintenance of calcitriol concentration was demonstrated in a study with CYP24A1 knockout mice and CYP24A1 and VDR double knockout mice [23, 24]. CYP24A1 deletion resulted in hypercalcaemia, impaired bone mineralization, and 50% decreased viability in experimental animals. On the contrary, CYP24A1 and VDR knockout mice did not show these characteristics. These findings suggest that increased 1,25(OH)2D level, not the absence of C23 or C24 degradation pathways, results in an abnormal phenotype.

CYPs can be divided into two main groups, based on localization within the cell: microsomal and mitochondrial (Table 1). Vitamin D metabolism includes both types. Neither microsomal nor mitochondrial CYPs work alone, but the electron transport chain is connected to them and is essential for the whole process. Mitochondrial vitamin D-related CYPs (e.g., CYP27A1, CYP27B1, and CYP24A1) require two additional electron-transporting proteins: ferredoxin reductase and ferredoxin. On the other hand, microsomal CYPs (e.g., CYP2R1) require only one additional protein, NADPH-cytochrome P450 reductase. All of the vitamin D-related CYPs include heme-bound structure involved in single or multiple hydroxylation process [25, 26].

Vitamin D present in the glomerular filtrate (bound to VDBP) is taken up by the kidney proximal tubular epithelial cells via the megalin/cubilin endocytic system (see Fig. 1) [27]. Degradation of VDBP in lysosome releases free 25(OH)D that is subsequently converted to 1,25(OH)2D by CYP27B1 located in the inner mitochondrial membrane. 1,25(OH)2D is then released to the circulation by passive diffusion across the cytoplasmatic membrane. Most of 1,25(OH)2D in plasma is bound to VDBP and albumin [28, 29]. Human CYP27B1 is a 507-amino acid protein (55 kDa) encoded by the gene localized on the 12q14.1 chromosome with a length of 4.8 kb [14, 26].

Fig. 1.

Vitamin D and glucose-related transporting mechanisms in the PTC. Vitamin D binds to VDBP in the tubular lumen, and the complex is transported by the megalin/cubilin system into the PTC. Inside the cell, vitamin D is released and metabolized (activated or degraded) in mitochondria while the megalin/cubilin complex is degraded in lysosomes. Vitamin D diffuses into interstitial space where it binds to VDBP. Glucose is transported to the PTC via SGLT2. Inhibition of SGLT2 by SGLT2i increases the amount of Na+ in the tubular lumen, which can increase resorption of phosphate and further alters the PTH-vitamin D-FGF23 axis. PTC, proximal tubule cell; VDBP, vitamin D binding protein; SGLT2, sodium-glucose co-transporter 2; NaPi-IIa/c, sodium-phosphate co-transporter IIa/c; GLUT2, glucose transporter 2.

Fig. 1.

Vitamin D and glucose-related transporting mechanisms in the PTC. Vitamin D binds to VDBP in the tubular lumen, and the complex is transported by the megalin/cubilin system into the PTC. Inside the cell, vitamin D is released and metabolized (activated or degraded) in mitochondria while the megalin/cubilin complex is degraded in lysosomes. Vitamin D diffuses into interstitial space where it binds to VDBP. Glucose is transported to the PTC via SGLT2. Inhibition of SGLT2 by SGLT2i increases the amount of Na+ in the tubular lumen, which can increase resorption of phosphate and further alters the PTH-vitamin D-FGF23 axis. PTC, proximal tubule cell; VDBP, vitamin D binding protein; SGLT2, sodium-glucose co-transporter 2; NaPi-IIa/c, sodium-phosphate co-transporter IIa/c; GLUT2, glucose transporter 2.

Close modal

As previously mentioned, proximal tubular epithelial cells are major players in 1α hydroxylation catalyzed by mitochondrial enzyme CYP27B1 [17]. Kidneys are able to ensure sufficient production of 1,25(OH)2D. However, a number of other cell types also expresses CYP27B1 (e.g., s, the brain, placenta, colon, pancreas, prostate, intestine, lung, macrophages, lymphocytes, parathyroid gland, osteoblasts, and chondrocytes, whose physiological significance is not clear in many cases) [30, 31].

As 1,25(OH)2D half-life is approximately 14 h [32], therefore, renal CYP27B1 activity must be tightly regulated. The main regulators include Ca2+, PO43−, parathyroid hormone (PTH), and fibroblast growth factor 23 (FGF23). A decrease in Ca2+ stimulates secretion of PTH, stimulating production and activity of CYP27B1 [33]. During normocalcaemia, circulating levels of PTH are insufficient to induce CYP27B1 expression. Hence, calcitonin regulation takes place [34]. Hyperphosphataemia stimulates FGF23 production in the bone. FGF23 inhibits CYP27B1 activity and indirectly decreases serum PO43− by downregulation of transcription, translation, and translocation of sodium-phosphate co-transporters in the proximal tubule [35, 36]. 1,25(OH)2D itself inhibits CYP27B1 transcription, since CYP27B1, same as the -CYP24A1 gene, contains vitamin D responsive element (VDRE) in a promoter region, establishing a negative feedback loop [26]. In fact, CYP24A1 regulates 1,25(OH)2D production independently on Ca2+ or PO43. Excess of 1,25(OH)2D downregulates CYP27B1 and upregulates CYP24A1 leading to its degradation. Depending on increased FGF23 level, PTH stimulates degradation of its mRNA. Vitamin D metabolism is strictly controlled to avoid an excessive amount of calcitriol [26, 37] which could lead to hypercalcaemia and hyperphosphataemia which in turn can be responsible for soft-tissue calcification and formation of kidney stones in the long term [1]. Renal regulation of CYP27B1 is shown in Figure 2. Extrarenal CYP27B1 are regulated by different mechanisms, including tissue-specific factors like cytokines [26].

Fig. 2.

Physiological regulation of calcium and phosphate metabolism. 1,25(OH)2D activated by CYP27B1 increases resorption of bones, therefore increasing sCa2+ and sPi concentration. It also increases calcium and phosphate reabsorption in the kidneys and absorption from the gut. PTH can increase bone and kidney mineral resorption as well as CYP27B1 levels and activity, establishing a feedback loop. All these mechanisms increase sCa2+ and sPi. Excess of sCa2+ and 1,25(OH)2D inhibits PTH production. On the contrary, increased serum phosphate increases the production of FGF23, which inhibits resorption of phosphate from the kidneys and CYP27B1 activity. The excess of 1,25(OH)2D activates CYP-24A1 and inhibits CYP27B1, establishing a negative feedback loop. sCa2+, serum calcium; sPi, serum phosphate; PTH, parathyroid hormone; FGF23, fibroblast growth factor 23; PTC, proximal tubule cell.

Fig. 2.

Physiological regulation of calcium and phosphate metabolism. 1,25(OH)2D activated by CYP27B1 increases resorption of bones, therefore increasing sCa2+ and sPi concentration. It also increases calcium and phosphate reabsorption in the kidneys and absorption from the gut. PTH can increase bone and kidney mineral resorption as well as CYP27B1 levels and activity, establishing a feedback loop. All these mechanisms increase sCa2+ and sPi. Excess of sCa2+ and 1,25(OH)2D inhibits PTH production. On the contrary, increased serum phosphate increases the production of FGF23, which inhibits resorption of phosphate from the kidneys and CYP27B1 activity. The excess of 1,25(OH)2D activates CYP-24A1 and inhibits CYP27B1, establishing a negative feedback loop. sCa2+, serum calcium; sPi, serum phosphate; PTH, parathyroid hormone; FGF23, fibroblast growth factor 23; PTC, proximal tubule cell.

Close modal

VDBP and albumin are the primary transporters of vitamin D metabolites in plasma. VDBP plasma concentrations are 2 orders of magnitude higher (5 × 10−6M) compared to its major circulating ligand 25(OH)D (5 × 10−8M), suggesting that only about 2% of VDBP is saturated. Under normal condition, <0.1% of 25(OH)D and <1% 1,25(OH)2D are present in free form [12, 29, 38]. Free vitamin D metabolites are crucial for most of the vitamin D effects besides metabolites bound to DBP are not available for most of the cells. Later research found that several tissues can transport vitamin D metabolites bound to VDBP into cells due to the megalin/cubilin transporting system. This system is present in kidneys PTC where it reabsorbs VDBP from primary urine, and this mechanism helps to maintain VDBP plasma concentration (Fig. 1) [27]. First finding of the crucial importance of the megalin transporter has been demonstrated by Nykjaer et al. [39] when they knocked out the gene for the megalin transporter in the mouse. Only 2% of megalin−/− mice survived to adulthood. They were significantly retarded in growth and exhibited a severe reduction in bone density caused by high VDBP and 25(OH)D urine excretion due to the missing megalin transporter compared to control animals. A study published 2 years later demonstrated that cubilin and megalin are physiologically important transporters working together. Cubilin-deficient dogs show 45 and 70% reduction in plasma 25(OH)D and 1,25(OH)2D, respectively, compared to healthy controls [40].

Megalin/cubilin transporting system also occurs in other tissues like the intestinal cells, placenta, and visceral yolk sac cells. Megalin is widely expressed across the body. It has also been found in the epithelium of the eye, thyroid and parathyroid glands, endometrium and lung alveoli, and many others [41].

1,25(OH)2D as a steroid hormone enters the cells via passive diffusion across the cytoplasmatic membrane and enters the cell core in the same way where it binds to VDR [9, 42]. VDR is a member of a large protein family that includes steroid hormones, vitamin A family metabolites, isoprenoids, fatty acid, thyroid hormones, and eicosanoids. Many receptors of this protein family have not known ligands and are called orphan receptors [12]. VDR acts in concert with other nuclear hormone receptors, mainly the retinoid X receptor. The heterodimer vitamin D-VDR binds to the VDRE and acts as a transcription factor. VDREs are commonly distributed across the genome and encode proteins that determine detoxification, bone metabolism (growth and remodelling), cell proliferation and differentiation, apoptosis, mammalian hair cycle, lipid metabolism, mineral homeostasis, immune and central nervous system function, and longevity [43]. Up to 10% of human genes are directly or indirectly responsive to VDR and 1,25(OH)2D [1, 44].

Most of the VDRE (>98%) are located around 400–500 base pairs upstream or downstream of the transcriptional start site of the vitamin D responsive gene [9, 43]. A typical sequence of VDRE is a tandem repeating oligonucleotide of 6 base pairs including a 3-nucleotide spacer. This repetition can slightly differ between genes within the genome or species (for more details, see [9, 43]).

As mentioned above, vitamin D has non-genomic effects as well. They include the activation of signalling molecules (e.g., phospholipase C, phospholipase A, and phosphatidylinositol-3 kinase) as well as quick generation of secondary messengers (e.g., Ca2+ and phosphatidylinositol 3,4,5 trisphosphate). Ca2+ and Cl channels are vitamin D responsive as well [45].

Ross et al. [46] published a recommendation for vitamin D plasma levels in 2011 concluding that vitamin D (measured as total 25(OH)D) at plasma concentration 16 ng/mL meets the needs of approximately 50% of the population, and 20 ng/mL covers 97.5% of the population. Moreover, the concentration above 50 ng/mL can cause adverse effects. Historically, vitamin D deficiency and insufficiency were not clearly defined (Table 2). The authors usually suggest vitamin D deficiency as 25(OH)D plasma concentration <20 ng/mL, insufficiency as 21–29 ng/mL, and optimal level of 25(OH)D above 30 ng/mL [47-49]. Previous research found that the ideal physiological concentration of PTH in plasma is achieved when 25(OH)D is above 32 ng/mL [50].

Table 2.

Recommendations on reference values of vitamin D

Recommendations on reference values of vitamin D
Recommendations on reference values of vitamin D

Several factors affect vitamin D status, such as sun exposure, skin pigmentation (less pigment allowing to synthesize more previtamin D), time of day, season, area of skin exposed to sunlight, body weight (only 1% of body fat increase was associated with 0.46 ± 0.22 ng/mL reduction in circulating 25(OH)D [51]), latitude, food-related vitamin D intake, and age (older people synthesizing less previtamin D) [48, 52]. Recommended daily intake and tolerable upper intake of vitamin D for adults are 600 IU/day and 4,000 IU/day, respectively [53]. Nevertheless, even doses around 10,000 IU/day are usually not associated with any adverse side effects. Overdose with vitamin D can cause hypercalcaemia and acute kidney injury, and it is usually caused by dosage equal or above 50,000 IU/day for a couple of weeks or months [46]. The recent study documented 19 people overdosed with vitamin D [54] with the average daily intake 100,000 IU/day orally or intramuscularly for 5–14 weeks.

Most popular supplements of vitamin D are cholecalciferol and ergocalciferol. In the 1930s, they were both assumed to be equal for humans, but in the second half of last century, pieces of evidence about cholecalciferol being a better option started to accumulate. Recently, cholecalciferol is preferred as a dietary vitamin D supplement. Trang et al. [55] showed that cholecalciferol could increase plasma 25(OH)D more effectively than ergocalciferol. Vitamin D3 is also maintaining 25(OH)D levels higher for a more extended period of time [56]. Recent review summarizing current knowledge about 25(OH)D supplementation suggests even higher efficiency of cholecalciferol in increasing plasma 25(OH)D levels compared to ergocalciferol with 1.7 to 8 higher potency depending on dosage, different pharmacokinetics, and basal 25(OH)D levels [52].

T2DM is considered to induce and maintain a low-grade chronic inflammation as a consequence of metabolic derangements related to decreased insulin sensitivity and impaired insulin secretion. Monocyte chemoattractant protein 1 is a chemokine produced by mesangial cells and renal tubular cells that play a crucial role in the recruitment of macrophages into the kidney, causing low-grade inflammation [57]. Together with many other pathways, vitamin D is implicated in the development of tissue and organ diabetic complications. Observational studies and some meta-analysis suggest that vitamin D deficiency increases the risk of T2DM development and the incidence of its complication [58, 59]. Vitamin D can stimulate transcription of the insulin receptor, insulin itself, and its concomitant secretion but also suppresses transcription of monocyte chemoattractant protein 1, therefore decreases inflammatory load to the kidneys [57]. As described above, low levels of vitamin D can cause hyperparathyroidism leading to dephosphorylation of glucose transporter-4 with subsequent decreased insulin-stimulated glucose transport. Therefore, vitamin D supplementation appears a promising strategy to prevent T2DM development (for more details, see [59]). However, a meta-analysis of published interventional studies with vitamin D supplementation in diabetic patients brings (rather typically) contradictory results. For example, Wu et al. [60] found that vitamin D supplementation significantly decreases HbA1c and fasting blood glucose levels in non-obese patients with T2DM and overt vitamin D deficiency, but not in those without insufficiency. On the contrary, a more recent meta-analysis did not find any statistically significant changes in HbA1c and fasting blood glucose levels [61]. A recent double-blind randomized clinical trial showed decreased insulin sensitivity after 6 months of cholecalciferol supplementation measured as HOMA-IR and also lower insulin levels [62]. These different results are probably due to different meta-analysis approach, leaving space for further research.

DKD is a common microvascular complication of diabetes mellitus with an incidence of approximately 30–40%. DKD is a major cause of the ESRD, renal transplantation, and mortality among patients with diabetes mellitus [63]. DKD is morphologically characterized by both glomerular (thickening of the glomerular basement membrane, expansion of the mesangium, glomerulosclerosis, and podocyte injury) and tubular changes, but the exact pathogenic mechanism – likely multiple and slightly different in T1DM versus T2DM – is still poorly understood [64]. Furthermore, significant inter-individual variability in the extent and type of glomerular/tubular involvement has been documented with genetic factors suspected to play a role [65].

Haemodynamic alterations, glucose and lipid metabolism disorders, non-enzymatic glycation, polyol pathway, proinflammatory cytokines, and oxidative stress were reported to be responsible for DKD onset and progression. However, present research suggests that abnormal inflammatory response is a crucial contributor to this disease [64]. Vila Cuenca et al. [66] recently showed that paricalcitol (a synthetic vitamin D analogue) modulates the endothelial barrier by enforcement of junctional VE-cadherin and the cortical F-actin cytoskeleton thus stabilizing the endothelial barrier in vitro. Vitamin D also acts as a renin-angiotensin-aldosterone system (RAAS) inhibitor, and its insufficiency can lead to increase of RAAS activity and eventually harm the renal tissues [67]. RAAS system is involved in the pathogenesis of DKD, and its inhibition is commonly used in patients with T2DM. A recent meta-analysis found that active vitamin D analogues in combination with RAAS inhibitors reduced proteinuria by 16% compared to standard RAAS-blocking therapy [68].

Several studies reported significantly decreased 25(OH)D plasma levels in a patient with DKD [69], leading to vitamin D insufficiency or deficiency overtime via several mechanisms: (i) the reduction in the number of functional nephrons. Second, (ii) CYP24A1 is overexpressed in diabetic patients, leading to elevated degradation of the principal vitamin D metabolite. Furthermore, (iii) CYP27B1 activity is decreased probably due to increased FGF23 levels – simultaneously increasing CYP24A1 transcription. Finally, (iv) proteins lost in urine including VDBP, megalin, and cubilin are all essential for vitamin D homeostasis [67]. All these factors result in impaired vitamin D homeostasis and decrease the level of both 25(OH)D and 1,25(OH)2D and cause secondary hyperparathyroidism.

A recent meta-analysis did not find any significant protecting effect of cholecalciferol or calcitriol supplementation in patients with DKD [3]. In contrast, another meta-analysis found a significant decrease in albuminuria after 24 weeks of paricalcitol supplementation (2 μg/day) [70]. Based on the current knowledge, despite the widespread belief that maintaining an optimal level of vitamin D might help to prevent diabetes mellitus and its complications, current evidence-based knowledge does not support a widespread vitamin D supplementation in diabetic patients [3, 59]. A recent long-term observational study found that T2DM patients with 25(OH)D <12 ng/L are at higher risk of cardiovascular mortality than those with higher 25(OH)D levels [71]. Further research is definitely required to clarify vitamin D effects on T2DM subtypes and various phenotypes of its complications.

Sodium-glucose linked co-transporter 2 (SGLT2) inhibitors (SGLT2i), also called gliflozins, are a relatively new class of drugs used as anti-diabetic treatment (with a realistic potential for repurposing to a non-diabetic population in the future). It acts via the inhibition of SGLT2 expressed in the proximal tubule. SGLT2 is responsible for reabsorption of up to 97% of glucose from primary urine (approximately 180 g/day under healthy condition). SGLT2i decrease glucose reabsorption approximately by 40–60%, thus producing glucosuria and subsequent decrease of glycaemia [72, 73]. Besides, as shown with many recent studies, SGLT2i are also able to decrease the following parameters: HbA1c (−0.79% [95% CI: −0.96% to −0.62%]), weight (−1.74 kg [95% CI: −2.03 to −1.45 kg]) [74], albuminuria (−43% [95% CI: −54% to −31%]) [75], systolic blood pressure (−3.77 mm Hg [95% CI: −4.65 to −2.90 mm Hg]) [74], and plasma uric acid levels (by 10–15% depending on dosage) [76]. By contrast, some adverse effects have been reported, for example, increased LDL cholesterol, increased risk of urinary infections with a hazard ratio (HR) (1.43 [95% CI: 1.05–1.94]) compared to placebo, and genital tract infection with HR (3.48 [95% CI: 2.33–5.20]) compared to placebo [74]. Gliflozins only rarely cause diabetic ketoacidosis (HR 10.80 [95% CI: 1.39–83.65]) [77]. Interestingly, two meta-analyses reported an increased risk of breast cancer in patients using gliflozins [74, 77].

Some authors also suggest the possibility of disrupted bone metabolism; inhibiting co-transport of Na+ and glucose might increase the electrochemical gradient for sodium in the proximal tubule. Excess of sodium boosts phosphate reabsorption via SLC34A1 (NaPi-IIa) and SLC34A3 (NaPi-IIc) co-transporters, and increased phosphate levels induce FGF23 expression. As mentioned above, FGF23 suppresses CYP27B1 expression and induces CYP24A1 expression. Therefore, circulating levels of 1,25(OH)2D might decrease. Lower 1,25(OH)2D levels reduce calcium absorption from the gastrointestinal tract, thereby promote secretion of PTH [35, 78]. Disruption of the PTH-vitamin D-FGF23 axis may lead to bone demineralization. Recent studies showed decreased levels of calcitriol and increased PTH and FGF23 in both diabetic patients and healthy controls [75, 78]. On the other hand, a recent meta-analysis did not find an increased risk for bone fracture [77, 79].

A recent study observed the effect of canagliflozin on bone mineral density (BMD) and bone biomarkers in a patient with type 2 diabetes [80]. A total of 716 patients followed for up to 104 weeks were divided into three groups receiving placebo and 100 and 300 mg of canagliflozin administered once daily. The authors found statistically significant differences in total hip BMD between placebo and both experimental groups with hip BMD decrease by 0.9 and 1.2% in the 100- and 300-mg canagliflozin group, respectively. No other statistical significances were found in measured parameters related to bone metabolism. The study also measured oestradiol, a hormone causing bone demineralization when its plasma levels are decreased. Compared to the placebo group, oestradiol decreased by 14.2 and 21.0% in 100- and 300-mg canagliflozin groups, respectively, at week 52. Canagliflozin use was also associated with increased β-CTX, a serum bone resorption marker. Interestingly, osteocalcin, a serum bone formation marker, was also increased significantly in both 100- and 300-mg canagliflozin groups compared to placebo at week 52. These results suggest augmented bone turnover in patients treated with canagliflozin, and further research is needed to elucidate the clinical significance of these findings.

Vitamin D and its metabolites play a crucial role in human health. Vitamin D is involved in calcium and phosphate homeostasis, and up to 10% of our genome is responsive to 1,25(OH)2D. Given the vitamin D deficiency/insufficiency and T2DM prevalence growing worldwide in the last decades, health burden for health care systems might be aggravated by their mutual pathophysiological interconnections. It is well documented that patients with DKD are excreting vitamin D and VDBP via urine, suggesting impairment of reuptake in PTC. Despite the broad range of established beneficial vitamin D effects in diabetes and CKD/DKD settings and thus importance to maintain physiological concentration in plasma, no definite conclusions can be drawn from the current literature on benefits of vitamin D supplementation in these individuals. Despite widespread recognized safety of SGLT2i, recent evidence suggests disruption of the PTH-vitamin D-FGF23 axis, resulting in impaired bone metabolism. Further research is needed to provide evidence about seriousness of metabolic disruption and its consequences.

The authors declare no conflicts of interest.

The study was supported by the NV18-01-00046 from the Ministry of Health of the Czech Republic.

The authors have contributed to the writing of this manuscript in the following way: conceptualization: David Galuška. Writing the original draft: David Galuška and Lukáš Pácal. Reviewing and editing final manuscript: David Galuška, Lukáš Pácal, and Kateřina Kaňková. All the authors contributed equally to the writing of the manuscript.

1.
Hossein-Nezhad
A
,
Holick
MF
.
Vitamin D for health: a global perspective
.
Mayo Clin Proc
.
2013 Jul
;
88
(
7
):
720
55
. .
2.
Prentice
A
.
Vitamin D deficiency: a global perspective
.
Nutr Rev
.
2008 Oct
;
66
(
10 Suppl 2
):
S153
64
. .
3.
Derakhshanian
H
,
Shab-Bidar
S
,
Speakman
JR
,
Nadimi
H
,
Djafarian
K
.
Vitamin D and diabetic nephropathy: a systematic review and meta-analysis
.
Nutrition
.
2015 Oct
;
31
(
10
):
1189
94
. .
4.
Senyigit
A
.
The association between 25-hydroxy vitamin D deficiency and diabetic complications in patients with type 2 diabetes mellitus
.
Diabetes Metab Syndr
.
2019 Mar 1
;
13
(
2
):
1381
6
. .
5.
Ali
MI
,
Fawaz
LA
,
Sedik
EE
,
Nour
ZA
,
Elsayed
RM
.
Vitamin D status in diabetic patients (type 2) and its relation to glycemic control & diabetic nephropathy
.
Diabetes Metab Syndr
.
2019 May – Jun
;
13
(
3
):
1971
3
. .
6.
Lytvyn
Y
,
Bjornstad
P
,
van Raalte
DH
,
Heerspink
HL
,
Cherney
DZI
.
The new biology of diabetic kidney disease: mechanisms and therapeutic implications
.
Endocr Rev
.
2019 Oct 21
;
41
:
202
31
.
7.
Martineau
AR
,
Jolliffe
DA
,
Hooper
RL
,
Greenberg
L
,
Aloia
JF
,
Bergman
P
, et al.
Vitamin D supplementation to prevent acute respiratory tract infections: systematic review and meta-analysis of individual participant data
.
BMJ
.
2017 Feb 15
;
356
:
i6583
[cited 2020 May 21].
8.
Alipio
M
.
Vitamin D supplementation could possibly improve clinical outcomes of patients infected with coronavirus-2019 (COVID-19) [Internet]
.
Rochester, NY
:
Social Science Research Network
;
2020 Apr
[cited 2020 May 15]. Report No.: ID 3571484. Available from: https://papers.ssrn.com/abstract=3571484.
9.
Makin
HLJ
,
Jones
G
,
Kaufmann
M
,
Calverley
MJ
.
Analysis of vitamins D, their metabolites and analogues
. In:
Makin
HLJ
,
Gower
DB
, editors.
Steroid analysis [Internet]
.
Dordrecht, Netherlands
:
Springer
;
2010
. p.
967
1096
[cited 2019 Jun 19].
10.
Smith
JE
,
Goodman
DS
.
The turnover and transport of vitamin D and of a polar metabolite with the properties of 25-hydroxycholecalciferol in human plasma
.
J Clin Invest
.
1971 Oct
;
50
(
10
):
2159
67
. .
11.
Kotsa
K
,
Grammatiki
M
.
Chapter 10: the role of vitamin D in the prevention and treatment of diabetes mellitus
. In:
Watson
RR
,
Preedy
VR
, editors.
Bioactive food as dietary interventions for diabetes (second edition) [Internet]
.
Cambridge
:
Academic Press
;
2019
. p.
157
74
[cited 2019 May 21]. Available from: http://www.sciencedirect.com/science/article/pii/B9780128138229000102.
12.
Bikle
D
.
Vitamin D: production, metabolism, and mechanisms of action
. In:
Feingold
KR
,
Anawalt
B
,
Boyce
A
,
Chrousos
G
,
Dungan
K
,
Grossman
A
, et al.
editors.
Endotext [Internet]
.
South Dartmouth, MA
:
MDText.com
;
2017
[cited 2019 May 21]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK278935/.
13.
Cheng
JB
,
Motola
DL
,
Mangelsdorf
DJ
,
Russell
DW
.
De-orphanization of cytochrome P450 2R1: a microsomal vitamin D 25-hydroxilase
.
J Biol Chem
.
2003 Sep 26
;
278
(
39
):
38084
93
. .
14.
Miller
WL
,
Portale
AA
.
Vitamin D 1 alpha-hydroxylase
.
Trends Endocrinol Metab
.
2000 Oct 1
;
11
(
8
):
315
9
. .
15.
Boron
W
,
Boulpaep
E
.
Medical physiology
. 3rd ed.
Philadeplhia
:
Elsevier
;
2017
. p.
1297
.
16.
Cheng
JB
,
Levine
MA
,
Bell
NH
,
Mangelsdorf
DJ
,
Russell
DW
.
Genetic evidence that the human CYP2R1 enzyme is a key vitamin D 25-hydroxylase
.
Proc Natl Acad Sci U S A
.
2004 May 18
;
101
(
20
):
7711
5
. .
17.
Takeyama
K
,
Kitanaka
S
,
Sato
T
,
Kobori
M
,
Yanagisawa
J
,
Kato
S
.
25-Hydroxyvitamin D3 1alpha-hydroxylase and vitamin D synthesis
.
Science
.
1997 Sep 19
;
277
(
5333
):
1827
30
. .
18.
Jones
G
,
Prosser
DE
,
Kaufmann
M
.
25-Hydroxyvitamin D-24-hydroxylase (CYP24A1): its important role in the degradation of vitamin D
.
Arch Biochem Biophys
.
2012 Jul 1
;
523
(
1
):
9
18
. .
19.
Horst
RL
.
25-OHD3-26,23-lactone: a metabolite of vitamin D3 that is 5 times more potent than 25-OHD3 in the rat plasma competitive protein binding radioassay
.
Biochem Biophys Res Commun
.
1979 Jul 12
;
89
(
1
):
286
93
. .
20.
Ross
AC
,
Yaktine
AL
,
Valle
HBD
.
Overview of vitamin D [Internet]
.
Washington, DC
:
National Academies Press
;
2011
[cited 2019 Jun 3]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK56061/.
21.
Prosser
DE
,
Kaufmann
M
,
O'Leary
B
,
Byford
V
,
Jones
G
.
Single A326G mutation converts human CYP24A1 from 25-OH-D3-24-hydroxylase into -23-hydroxylase, generating 1alpha,25-(OH)2D3-26,23-lactone
.
Proc Natl Acad Sci U S A
.
2007 Jul 31
;
104
(
31
):
12673
8
. .
22.
Ishizuka
S
,
Kurihara
N
,
Hiruma
Y
,
Miura
D
,
Namekawa
J
,
Tamura
A
, et al.
1alpha,25-Dihydroxyvitamin D(3)-26,23-lactam analogues function as vitamin D receptor antagonists in human and rodent cells
.
J Steroid Biochem Mol Biol
.
2008 Jun
;
110
(
3–5
):
269
77
. .
23.
Masuda
S
,
Byford
V
,
Arabian
A
,
Sakai
Y
,
Demay
MB
,
St-Arnaud
R
, et al.
Altered pharmacokinetics of 1alpha,25-dihydroxyvitamin D3 and 25-hydroxyvitamin D3 in the blood and tissues of the 25-hydroxyvitamin D-24-hydroxylase (Cyp24a1) null mouse
.
Endocrinology
.
2005 Feb
;
146
(
2
):
825
34
. .
24.
St-Arnaud
R
,
Arabian
A
,
Travers
R
,
Barletta
F
,
Raval-Pandya
M
,
Chapin
K
, et al.
Deficient mineralization of intramembranous bone in vitamin D-24-hydroxylase-ablated mice is due to elevated 1,25-dihydroxyvitamin D and not to the absence of 24,25-dihydroxyvitamin D
.
Endocrinology
.
2000 Jul
;
141
(
7
):
2658
66
. .
25.
Prosser
DE
,
Jones
G
.
Enzymes involved in the activation and inactivation of vitamin D
.
Trends Biochem Sci
.
2004 Dec 1
;
29
(
12
):
664
73
. .
26.
Jones
G
,
Prosser
DE
,
Kaufmann
M
.
Cytochrome P450-mediated metabolism of vitamin D
.
J Lipid Res
.
2014 Jan
;
55
(
1
):
13
31
. .
27.
Nielsen
R
,
Christensen
EI
,
Birn
H
.
Megalin and cubilin in proximal tubule protein reabsorption: from experimental models to human disease
.
Kidney Int
.
2016 Jan
;
89
(
1
):
58
67
. .
28.
Chesney
RW
.
Interactions of vitamin D and the proximal tubule
.
Pediatr Nephrol
.
2016 Jan
;
31
(
1
):
7
14
. .
29.
Cooke
NE
,
Haddad
JG
.
Vitamin D binding protein (Gc-globulin)
.
Endocr Rev
.
1989 Aug 1
;
10
(
3
):
294
307
. .
30.
Bikle
DD
.
Extra renal Ssnthesis of 1,25-dihydroxyvitamin D and its health implications
.
Clinic Rev Bone Miner Metab
.
2009 Jun 1
;
7
(
2
):
114
25
. .
31.
Zehnder
D
,
Bland
R
,
Williams
MC
,
McNinch
RW
,
Howie
AJ
,
Stewart
PM
, et al.
Extrarenal expression of 25-hydroxyvitamin d(3)-1 alpha-hydroxylase
.
J Clin Endocrinol Metab
.
2001 Feb
;
86
(
2
):
888
94
. .
32.
Barbara Mawer
E
,
Davies
M
,
Backhouse
J
,
Hill
LF
,
Taylor
CM
.
Metabolic fate of administered 1,25-dihydroxycholecalciferol in controls and in patients with hypoparathyroidism
.
Lancet
.
1976 Jun 5
;
307
(
7971
):
1203
6
.
33.
Brenza
HL
,
Kimmel-Jehan
C
,
Jehan
F
,
Shinki
T
,
Wakino
S
,
Anazawa
H
, et al.
Parathyroid hormone activation of the 25-hydroxyvitamin D3-1alpha-hydroxylase gene promoter
.
Proc Natl Acad Sci U S A
.
1998 Feb 17
;
95
(
4
):
1387
91
. .
34.
Shinki
T
,
Ueno
Y
,
DeLuca
HF
,
Suda
T
.
Calcitonin is a major regulator for the expression of renal 25-hydroxyvitamin D3-1alpha-hydroxylase gene in normocalcemic rats
.
Proc Natl Acad Sci U S A
.
1999 Jul 6
;
96
(
14
):
8253
8
. .
35.
Blau
JE
,
Collins
MT
.
The PTH-vitamin D-FGF23 axis
.
Rev Endocr Metab Disord
.
2015 Jun 1
;
16
(
2
):
165
74
. .
36.
Liu
S
,
Quarles
LD
.
How fibroblast growth factor 23 works
.
J Am Soc Nephrol
.
2007 Jun 1
;
18
(
6
):
1637
47
. .
37.
Kägi
L
,
Bettoni
C
,
Pastor-Arroyo
EM
,
Schnitzbauer
U
,
Hernando
N
,
Wagner
CA
.
Regulation of vitamin D metabolizing enzymes in murine renal and extrarenal tissues by dietary phosphate, FGF23, and 1,25(OH)2D3
.
PLoS One
.
2018
;
13
(
5
):
e0195427
. .
38.
Dastani
Z
,
Berger
C
,
Langsetmo
L
,
Fu
L
,
Wong
BY
,
Malik
S
, et al.
In healthy adults, biological activity of vitamin D, as assessed by serum PTH, is largely independent of DBP concentrations
.
J Bone Miner Res
.
2014
;
29
(
2
):
494
9
. .
39.
Nykjaer
A
,
Dragun
D
,
Walther
D
,
Vorum
H
,
Jacobsen
C
,
Herz
J
, et al.
An endocytic pathway essential for renal uptake and activation of the steroid 25-(OH) vitamin D3
.
Cell
.
1999 Feb 19
;
96
(
4
):
507
15
. .
40.
Nykjaer
A
,
Fyfe
JC
,
Kozyraki
R
,
Leheste
JR
,
Jacobsen
C
,
Nielsen
MS
, et al.
Cubilin dysfunction causes abnormal metabolism of the steroid hormone 25(OH) vitamin D(3)
.
Proc Natl Acad Sci U S A
.
2001 Nov 20
;
98
(
24
):
13895
900
. .
41.
Christensen
EI
,
Birn
H
.
Megalin and cubilin: multifunctional endocytic receptors
.
Nat Rev Mol Cell Biol
.
2002 Apr
;
3
(
4
):
256
. .
42.
Mendel
CM
.
The free hormone hypothesis: a physiologically based mathematical model
.
Endocr Rev
.
1989 Aug 1
;
10
(
3
):
232
74
. .
43.
Haussler
MR
,
Whitfield
GK
,
Haussler
CA
,
Sabir
MS
,
Khan
Z
,
Sandoval
R
, et al.
Chapter eight: 1,25-dihydroxyvitamin D and klotho: a tale of two renal hormones coming of age
. In:
Litwack
G
, editor.
Vitamins & hormones [Internet]
.
Cambridge
:
Academic Press
;
2016
. p.
165
230
[cited 2019 Jun 11] (Vitamin D Hormone; vol. 100). Available from: http://www.sciencedirect.com/science/article/pii/S0083672915000692.
44.
Bouillon
R
,
Carmeliet
G
,
Verlinden
L
,
van Etten
E
,
Verstuyf
A
,
Luderer
HF
, et al.
Vitamin D and human health: lessons from vitamin D receptor null mice
.
Endocr Rev
.
2008 Oct
;
29
(
6
):
726
76
. .
45.
Hii
CS
,
Ferrante
A
.
The non-genomic actions of vitamin D
.
Nutrients
.
2016 Mar 2
;
8
(
3
):
135
. .
46.
Ross
AC
,
Yaktine
AL
,
Del Valle
HB
, editors.
Dietary reference intakes for calcium and vitamin D [Internet]
.
Washington, DC
:
National Academies Press
;
2011
[cited 2020 May 21]. The National Academies Collection: Reports funded by National Institutes of Health. Available from: http://www.ncbi.nlm.nih.gov/books/NBK56070/.
47.
Holick
MF
.
Vitamin D deficiency
.
N Engl J Med
.
2007 Jul 19
;
357
(
3
):
266
81
. .
48.
Rovner
AJ
,
O’Brien
KO
.
Hypovitaminosis D among healthy children in the United States: a review of the current evidence
.
Arch Pediatr Adolesc Med
.
2008 Jun
;
162
(
6
):
513
9
.
49.
Sahota
O
.
Understanding vitamin D deficiency
.
Age Ageing
.
2014 Sep
;
43
(
5
):
589
91
. .
50.
Holick
MF
.
The vitamin D epidemic and its health consequences
.
J Nutr
.
2005 Nov
;
135
(
11
):
2739S
48S
. .
51.
Lenders
CM
,
Feldman
HA
,
Von Scheven
E
,
Merewood
A
,
Sweeney
C
,
Wilson
DM
, et al.
Relation of body fat indexes to vitamin D status and deficiency among obese adolescents
.
Am J Clin Nutr
.
2009 Sep
;
90
(
3
):
459
67
. .
52.
Cesareo
R
,
Falchetti
A
,
Attanasio
R
,
Tabacco
G
,
Naciu
AM
,
Palermo
A
.
Hypovitaminosis D: is it time to consider the use of calcifediol?
Nutrients
.
2019 May 6
;
11
(
5
). .
53.
Ross
AC
,
Manson
JE
,
Abrams
SA
,
Aloia
JF
,
Brannon
PM
,
Clinton
SK
, et al.
The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know
.
J Clin Endocrinol Metab
.
2011 Jan
;
96
(
1
):
53
8
.
54.
Chowdry
AM
,
Azad
H
,
Najar
MS
,
Mir
I
.
Acute kidney injury due to overcorrection of hypovitaminosis D: a tertiary center experience in the Kashmir Valley of India
.
Saudi J Kidney Dis Transpl
.
2017 Nov–Dec
;
28
(
6
):
1321
9
. .
55.
Trang
HM
,
Cole
DE
,
Rubin
LA
,
Pierratos
A
,
Siu
S
,
Vieth
R
.
Evidence that vitamin D3 increases serum 25-hydroxyvitamin D more efficiently than does vitamin D2
.
Am J Clin Nutr
.
1998 Oct
;
68
(
4
):
854
8
. .
56.
Armas
LA
,
Hollis
BW
,
Heaney
RP
.
Vitamin D2 is much less effective than vitamin D3 in humans
.
J Clin Endocrinol Metab
.
2004 Nov
;
89
(
11
):
5387
91
. .
57.
Zhang
Z
,
Yuan
W
,
Sun
L
,
Szeto
FL
,
Wong
KE
,
Li
X
, et al.
1,25-Dihydroxyvitamin D3 targeting of NF-kappaB suppresses high glucose-induced MCP-1 expression in mesangial cells
.
Kidney Int
.
2007 Jul 2
;
72
(
2
):
193
201
. .
58.
Chiu
KC
,
Chu
A
,
Go
VL
,
Saad
MF
.
Hypovitaminosis D is associated with insulin resistance and beta cell dysfunction
.
Am J Clin Nutr
.
2004 May
;
79
(
5
):
820
5
. .
59.
Grammatiki
M
,
Karras
S
,
Kotsa
K
.
The role of vitamin D in the pathogenesis and treatment of diabetes mellitus: a narrative review
.
Hormones
.
2018 Sep 25
;
18
:
37
48
.
60.
Wu
C
,
Qiu
S
,
Zhu
X
,
Li
L
.
Vitamin D supplementation and glycemic control in type 2 diabetes patients: a systematic review and meta-analysis
.
Metab Clin Exp
.
2017 Aug 1
;
73
:
67
76
. .
61.
Li
X
,
Liu
Y
,
Zheng
Y
,
Wang
P
,
Zhang
Y
.
The effect of vitamin D supplementation on glycemic control in type 2 diabetes patients: a systematic review and meta-analysis
.
Nutrients
.
2018 Mar 19
;
10
(
3
):
375
[cited 2019 Jul 29]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5872793/.
62.
Niroomand
M
,
Fotouhi
A
,
Irannejad
N
,
Hosseinpanah
F
.
Does high-dose vitamin D supplementation impact insulin resistance and risk of development of diabetes in patients with pre-diabetes? A double-blind randomized clinical trial
.
Diabetes Res Clin Pract
.
2019 Feb 1
;
148
:
1
9
. .
63.
Anders
HJ
,
Huber
TB
,
Isermann
B
,
Schiffer
M
.
CKD in diabetes: diabetic kidney disease versus nondiabetic kidney disease
.
Nat Rev Nephrol
.
2018 Jun
;
14
(
6
):
361
77
. .
64.
Hu
X
,
Liu
W
,
Yan
Y
,
Liu
H
,
Huang
Q
,
Xiao
Y
, et al.
Vitamin D protects against diabetic nephropathy: evidence-based effectiveness and mechanism
.
Eur J Pharmacol
.
2019 Feb 15
;
845
:
91
8
. .
65.
Li
M
,
Pezzolesi
MG
.
Advances in understanding the genetic basis of diabetic kidney disease
.
Acta Diabetol
.
2018 Nov 1
;
55
(
11
):
1093
104
. .
66.
Vila Cuenca
M
,
Ferrantelli
E
,
Meinster
E
,
Pouw
SM
,
Kovačević
I
,
de Menezes
RX
, et al.
Vitamin D attenuates endothelial dysfunction in uremic rats and maintains human endothelial stability
.
J Am Heart Assoc
.
2018 Sep 4
;
7
(
17
):
e008776
.
67.
Plum
LA
,
Zella
JB
.
Vitamin D compounds and diabetic nephropathy
.
Arch Biochem Biophys
.
2012 Jul 1
;
523
(
1
):
87
94
. .
68.
de Borst
MH
,
Hajhosseiny
R
,
Tamez
H
,
Wenger
J
,
Thadhani
R
,
Goldsmith
DJA
.
Active vitamin D treatment for reduction of residual proteinuria: a systematic review
.
J Am Soc Nephrol
.
2013 Nov 1
;
24
(
11
):
1863
71
.
69.
Xiao
X
,
Wang
Y
,
Hou
Y
,
Han
F
,
Ren
J
,
Hu
Z
.
Vitamin D deficiency and related risk factors in patients with diabetic nephropathy
.
J Int Med Res
.
2016 Jun
;
44
(
3
):
673
84
. .
70.
de Zeeuw
D
,
Agarwal
R
,
Amdahl
M
,
Audhya
P
,
Coyne
D
,
Garimella
T
, et al.
Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial
.
Lancet
.
2010 Nov 6
;
376
(
9752
):
1543
51
. .
71.
Al-khalidi
B
,
Kuk
JL
,
Ardern
CI
.
Lifetime risk of cardiometabolic mortality according to vitamin D status of middle and older-aged adults: NHANES III mortality follow-up
.
J Steroid Biochem Mol Biol
.
2019 Feb 1
;
186
:
34
41
. .
72.
Satirapoj
B
.
Sodium-glucose cotransporter 2 inhibitors with renoprotective effects
.
Kidney Dis
.
2017 Jul
;
3
(
1
):
24
32
. .
73.
Milder
TY
,
Stocker
SL
,
Samocha-Bonet
D
,
Day
RO
,
Greenfield
JR
.
Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: cardiovascular and renal benefits in patients with chronic kidney disease
.
Eur J Clin Pharmacol
.
2019 Aug 3
;
75
:
1481
90
[cited 2019 Aug 28].
74.
Vasilakou
D
,
Karagiannis
T
,
Athanasiadou
E
,
Mainou
M
,
Liakos
A
,
Bekiari
E
, et al.
Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis
.
Ann Intern Med
.
2013 Aug 20
;
159
(
4
):
262
74
. .
75.
de Jong
MA
,
Petrykiv
SI
,
Laverman
GD
,
van Herwaarden
AE
,
de Zeeuw
D
,
Bakker
SJL
, et al.
Effects of dapagliflozin on circulating markers of phosphate homeostasis
.
Clin J Am Soc Nephrol
.
2019 Jan 7
;
14
(
1
):
66
73
.
76.
Bailey
CJ
,
Gross
JL
,
Pieters
A
,
Bastien
A
,
List
JF
.
Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial
.
Lancet
.
2010 Jun 26
;
375
(
9733
):
2223
33
. .
77.
Perkovic
V
,
Jardine
MJ
,
Neal
B
,
Bompoint
S
,
Heerspink
HJL
,
Charytan
DM
, et al.
Canagliflozin and renal outcomes in type 2 diabetes and nephropathy
.
N Engl J Med
.
2019 Jun 13
;
380
(
24
):
2295
306
. .
78.
Blau
JE
,
Bauman
V
,
Conway
EM
,
Piaggi
P
,
Walter
MF
,
Wright
EC
, et al.
Canagliflozin triggers the FGF23/1,25-dihydroxyvitamin D/PTH axis in healthy volunteers in a randomized crossover study
.
JCI Insight
.
2018 Apr 19
;
3
(
8
):
e99123
. .
79.
Wu
JH
,
Foote
C
,
Blomster
J
,
Toyama
T
,
Perkovic
V
,
Sundström
J
, et al.
Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis
.
Lancet Diabetes Endocrinol
.
2016
;
4
(
5
):
411
9
. .
80.
Bilezikian
JP
,
Watts
NB
,
Usiskin
K
,
Polidori
D
,
Fung
A
,
Sullivan
D
, et al.
Evaluation of bone mineral density and bone biomarkers in patients with type 2 diabetes treated with canagliflozin
.
J Clin Endocrinol Metab
.
2016 Jan
;
101
(
1
):
44
51
. .
Open Access License / Drug Dosage / Disclaimer
This article is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC). Usage and distribution for commercial purposes requires written permission. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.